

# Zhao Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6687782/publications.pdf>

Version: 2024-02-01

31  
papers

206  
citations

1163117

8  
h-index

1125743

13  
g-index

31  
all docs

31  
docs citations

31  
times ranked

390  
citing authors

#	ARTICLE	IF	CITATIONS
1	MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer. Cellular Physiology and Biochemistry, 2017, 43, 2505-2515.	1.6	64
2	The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. British Journal of Haematology, 2020, 189, 908-912.	2.5	16
3	Associations between CYP1A1 rs1048943 A > G and rs4646903 T > C genetic variations and colorectal cancer risk: Proof from 26 case-control studies. Oncotarget, 2016, 7, 51365-51374.	1.8	15
4	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Cancer Research and Treatment, 2019, 51, 919-932.	3.0	14
5	Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study. Leukemia and Lymphoma, 2018, 59, 2821-2828.	1.3	11
6	Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. Leukemia and Lymphoma, 2018, 59, 2911-2916.	1.3	11
7	Platelet-derived alpha-granules are associated with inflammation in patients with NK/T-cell lymphoma-associated hemophagocytic syndrome. Cytokine, 2020, 126, 154878.	3.2	9
8	Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen. Frontiers in Oncology, 2020, 10, 1011.	2.8	9
9	Association between GSTP1 Ile105Val polymorphism and urinary system cancer risk: evidence from 51 studies. OncoTargets and Therapy, 2016, 9, 3565.	2.0	8
10	A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. American Journal of Hematology, 2019, 94, E122-E124.	4.1	7
11	Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified. Frontiers in Oncology, 2021, 11, 607145.	2.8	6
12	A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment. Annals of Hematology, 2020, 99, 2811-2819.	1.8	5
13	Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R. Lung Cancer, 2020, 144, 87-89.	2.0	4
14	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. Acta Pharmacologica Sinica, 2021, 42, 641-647.	6.1	4
15	A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1842-1849.	1.3	3
16	A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy. Cancer Management and Research, 2020, Volume 12, 1981-1990.	1.9	3
17	Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Leukemia and Lymphoma, 2021, 62, 571-580.	1.3	3
18	Extranodal natural killer T-cell lymphoma, nasal-type: A new staging system from CSWOG: A multicenter study.. Journal of Clinical Oncology, 2014, 32, 8552-8552.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Rituximab exposure response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 680-690.	3.1	3
20	Prevention of thrombocytopenia using thrombopoietin in high-dose cytarabine treatment of non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e19532-e19532.	1.6	2
21	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 8831-8839.	1.9	2
22	Prospective study of thalidomide maintenance therapy in high-risk diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e19551-e19551.	1.6	1
23	Randomized, open-label, phase III trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 7560-7560.	1.6	1
24	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2022, 13, 788824.	3.5	1
25	A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-world multicenter study. <i>BMC Cancer</i> , 2022, 22, 45.	2.6	1
26	Perspective study of intensive therapy makes newly diagnosed distant metastatic nasopharyngeal cancer (mNPC) potential curable. <i>Journal of Clinical Oncology</i> , 2014, 32, e17007-e17007.	1.6	0
27	Early negative circulating EBV DNA as prediction of survival in extranodal NK/T-cell lymphoma, nasal type (ENKL). <i>Journal of Clinical Oncology</i> , 2014, 32, 8562-8562.	1.6	0
28	A prospective study of R-CHOP chemotherapy induced pulmonary pneumonia in diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e19508-e19508.	1.6	0
29	Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 7553-7553.	1.6	0
30	PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal type: A prospective study. <i>Journal of Clinical Oncology</i> , 2019, 37, 7537-7537.	1.6	0
31	A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with rituximab. <i>Journal of Clinical Oncology</i> , 2019, 37, e13518-e13518.	1.6	0